Literature DB >> 34933050

A Darwinian perspective on tumor immune evasion.

Julieann Puleo1, Kornelia Polyak2.   

Abstract

Evading immune-mediated destruction is a critical step of tumor evolution and the immune system is one of the strongest selective pressures during tumorigenesis. Analyzing tumor immune evasion from a Darwinian perspective may provide critical insight into the mechanisms of primary immune escape and acquired resistance to immunotherapy. Here, we review the steps required to mount an anti-tumor immune response, describe how each of these steps is disrupted during tumorigenesis, list therapeutic strategies to restore anti-tumor immunity, and discuss each mechanism of immune and therapeutic evasion from a Darwinian perspective.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Immune evasion; Tumor evolution

Mesh:

Year:  2021        PMID: 34933050      PMCID: PMC8818030          DOI: 10.1016/j.bbcan.2021.188671

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN: 0304-419X            Impact factor:   10.680


  129 in total

Review 1.  Dendritic cells in cancer: the role revisited.

Authors:  Filippo Veglia; Dmitry I Gabrilovich
Journal:  Curr Opin Immunol       Date:  2017-02-10       Impact factor: 7.486

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 3.  VEGF in Signaling and Disease: Beyond Discovery and Development.

Authors:  Rajendra S Apte; Daniel S Chen; Napoleone Ferrara
Journal:  Cell       Date:  2019-03-07       Impact factor: 41.582

4.  Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma.

Authors:  Takahide Nejo; Hirokazu Matsushita; Takahiro Karasaki; Masashi Nomura; Kuniaki Saito; Shota Tanaka; Shunsaku Takayanagi; Taijun Hana; Satoshi Takahashi; Yosuke Kitagawa; Tsukasa Koike; Yukari Kobayashi; Genta Nagae; Shogo Yamamoto; Hiroki Ueda; Kenji Tatsuno; Yoshitaka Narita; Motoo Nagane; Keisuke Ueki; Ryo Nishikawa; Hiroyuki Aburatani; Akitake Mukasa; Nobuhito Saito; Kazuhiro Kakimi
Journal:  Cancer Immunol Res       Date:  2019-05-14       Impact factor: 11.151

5.  CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes.

Authors:  Rinke Bos; Linda A Sherman
Journal:  Cancer Res       Date:  2010-10-12       Impact factor: 12.701

Review 6.  Targeting Treg cells in cancer immunotherapy.

Authors:  Atsushi Tanaka; Shimon Sakaguchi
Journal:  Eur J Immunol       Date:  2019-07-05       Impact factor: 5.532

7.  Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.

Authors:  Jing Liu; Stephen J Blake; Michelle C R Yong; Heidi Harjunpää; Shin Foong Ngiow; Kazuyoshi Takeda; Arabella Young; Jake S O'Donnell; Stacey Allen; Mark J Smyth; Michele W L Teng
Journal:  Cancer Discov       Date:  2016-09-23       Impact factor: 39.397

Review 8.  Tissue-resident memory T cells at the center of immunity to solid tumors.

Authors:  Derk Amsen; Klaas P J M van Gisbergen; Pleun Hombrink; Rene A W van Lier
Journal:  Nat Immunol       Date:  2018-05-18       Impact factor: 25.606

Review 9.  CD8(+) T cells: foot soldiers of the immune system.

Authors:  Nu Zhang; Michael J Bevan
Journal:  Immunity       Date:  2011-08-26       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.